A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults

NCT02990325 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

36

Enrollment

INDUSTRY

Sponsor class

Conditions

HIV Infections
Health Volunteers

Interventions

DRUG: ABX464 150mg
DRUG: ABX464 50mg
DRUG: ABX464 50mg

Sponsor

Abivax S.A.